FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2338950868> ?p ?o ?g. }

• W2338950868 abstract "Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PABackgroundHyper-activation of the Cyclin D-CDK4/6 signaling pathway is a common feature of neuroblastoma. Previously, it has been shown that while a majority of preclinical models of neuroblastoma are highly sensitive to pharmacologic inhibition of CDK4/6 by LEE011 (Novartis Oncology), a subset are remarkably resistant. In an effort to aid in the selection of a patient population that will best benefit from this therapy, we sought to identify genomic biomarkers of response to CDK4/6 inhibition.MethodsLEE011 IC50 values were determined using the RT-CES cell impedance assay, and gene expression was established at baseline using HuGene 1.0ST microarrays (Affymetrix). Expression data was then coupled with IC50 values to identify a set of genes significantly associated with LEE011 response via Pearson correlation. Using this gene set, a Lasso linear regression model was built in order to predict sensitivity to LEE011 based upon the expression of a subset of genes chosen to be most predictive of response. The model was tested in a separate cohort of neuroblastoma cell lines by comparing predicted responses to LEE011 with experimentally determined LEE011 IC50 values. Functional RNAi and over-expression studies are ongoing in order to validate genes identified to be correlated with or predictive of response.ResultsThe Lasso model was able to predict the response of neuroblastoma cell lines to LEE011 based upon the expression pattern of 11 genes. A comparison of Lasso predictions to the LEE011 IC50 values of a separate panel of cell lines yielded a correlation coefficient of 0.63. The correlation of predicted to actual response across our entire cell line panel was 0.96, suggesting that response to CDK4/6 inhibition by LEE011 can be accurately predicted based on the expression of these genes. Of the 11 genes, NMI (N-myc and stat interactor) was prioritized for further validation and functional studies as it was identified by Pearson correlation to be the third most correlated gene with response (r = 0.86; p = 3.1×10-7) and because it interacts with MYCN, a known prognostic indicator in neuroblastoma. We next showed that NMI was expressed higher at both the mRNA and protein levels in neuroblastoma cell lines resistant (N = 6) to LEE011 compared to those demonstrating sensitivity to the compound (N = 16). Studies are ongoing to confirm the role of NMI as a predictor of resistance as well as to assess its contribution, if any, in desensitizing neuroblastoma to CDK4/6 inhibition.ConclusionsWe have identified NMI as a candidate biomarker of resistance to CDK4/6 inhibition in preclinical models of neuroblastoma. Further validation of this gene as a biomarker may ultimately help drive clinical decisions in selecting patients who would most benefit from CDK4/6 inhibition therapies, as well as in identifying novel drugs to combine with LEE011 for the treatment of neuroblastoma patients.Note: This abstract was not presented at the meeting.Citation Format: JulieAnn Rader, Pichai Raman, Lori Hart, Mike Russell, Kristina A. Cole, John M. Maris. NMI as a biomarker of response to CDK4/6 inhibition in a preclinical model of neuroblastoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4305. doi:10.1158/1538-7445.AM2015-4305" @default.
• W2338950868 created "2016-06-24" @default.
• W2338950868 creator A5005796905 @default.
• W2338950868 creator A5005797590 @default.
• W2338950868 creator A5008979088 @default.
• W2338950868 creator A5034411606 @default.
• W2338950868 creator A5041038775 @default.
• W2338950868 creator A5068529122 @default.
• W2338950868 date "2015-08-01" @default.
• W2338950868 modified "2023-09-26" @default.
• W2338950868 title "Abstract 4305: NMI as a biomarker of response to CDK4/6 inhibition in a preclinical model of neuroblastoma" @default.
• W2338950868 doi "https://doi.org/10.1158/1538-7445.am2015-4305" @default.
• W2338950868 hasPublicationYear "2015" @default.
• W2338950868 type Work @default.
• W2338950868 sameAs 2338950868 @default.
• W2338950868 citedByCount "0" @default.
• W2338950868 crossrefType "proceedings-article" @default.
• W2338950868 hasAuthorship W2338950868A5005796905 @default.
• W2338950868 hasAuthorship W2338950868A5005797590 @default.
• W2338950868 hasAuthorship W2338950868A5008979088 @default.
• W2338950868 hasAuthorship W2338950868A5034411606 @default.
• W2338950868 hasAuthorship W2338950868A5041038775 @default.
• W2338950868 hasAuthorship W2338950868A5068529122 @default.
• W2338950868 hasConcept C104317684 @default.
• W2338950868 hasConcept C124320809 @default.
• W2338950868 hasConcept C143998085 @default.
• W2338950868 hasConcept C199649820 @default.
• W2338950868 hasConcept C2776715637 @default.
• W2338950868 hasConcept C29537977 @default.
• W2338950868 hasConcept C54355233 @default.
• W2338950868 hasConcept C60644358 @default.
• W2338950868 hasConcept C71924100 @default.
• W2338950868 hasConcept C81885089 @default.
• W2338950868 hasConcept C86803240 @default.
• W2338950868 hasConceptScore W2338950868C104317684 @default.
• W2338950868 hasConceptScore W2338950868C124320809 @default.
• W2338950868 hasConceptScore W2338950868C143998085 @default.
• W2338950868 hasConceptScore W2338950868C199649820 @default.
• W2338950868 hasConceptScore W2338950868C2776715637 @default.
• W2338950868 hasConceptScore W2338950868C29537977 @default.
• W2338950868 hasConceptScore W2338950868C54355233 @default.
• W2338950868 hasConceptScore W2338950868C60644358 @default.
• W2338950868 hasConceptScore W2338950868C71924100 @default.
• W2338950868 hasConceptScore W2338950868C81885089 @default.
• W2338950868 hasConceptScore W2338950868C86803240 @default.
• W2338950868 hasLocation W23389508681 @default.
• W2338950868 hasOpenAccess W2338950868 @default.
• W2338950868 hasPrimaryLocation W23389508681 @default.
• W2338950868 hasRelatedWork W1544022927 @default.
• W2338950868 hasRelatedWork W1970858206 @default.
• W2338950868 hasRelatedWork W1974446478 @default.
• W2338950868 hasRelatedWork W1997381629 @default.
• W2338950868 hasRelatedWork W2042660215 @default.
• W2338950868 hasRelatedWork W2046757754 @default.
• W2338950868 hasRelatedWork W2062689591 @default.
• W2338950868 hasRelatedWork W2072138655 @default.
• W2338950868 hasRelatedWork W2084929120 @default.
• W2338950868 hasRelatedWork W2175520075 @default.
• W2338950868 hasRelatedWork W2230946999 @default.
• W2338950868 hasRelatedWork W2232287197 @default.
• W2338950868 hasRelatedWork W2333713217 @default.
• W2338950868 hasRelatedWork W2339873879 @default.
• W2338950868 hasRelatedWork W2785525961 @default.
• W2338950868 hasRelatedWork W2885043479 @default.
• W2338950868 hasRelatedWork W3083374382 @default.
• W2338950868 hasRelatedWork W3181336465 @default.
• W2338950868 hasRelatedWork W3191195384 @default.
• W2338950868 hasRelatedWork W3207754762 @default.
• W2338950868 isParatext "false" @default.
• W2338950868 isRetracted "false" @default.
• W2338950868 magId "2338950868" @default.
• W2338950868 workType "article" @default.